Vanguard Group Inc made a significant addition to its portfolio by acquiring 9,018,094 shares of Edwards Lifesciences Corp ...

EW saw its stock trading at around $95 in June 2022, just before the Fed started increasing rates, and it’s still trading 30% ...

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $81.0, with a high ...

To start with, Edwards Lifesciences' ROE looks acceptable. Further, the company's ROE compares quite favorably to the industry average of 11%. Probably as a result of this, Edwards Lifesciences was ...

Shares of Edwards Lifesciences Corp. EW inched 0.18% higher to $65.49 Friday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 0.90% ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Edwards Lifesciences (EW – Research Report), ...

Edwards Lifesciences Corp (EW) stock saw a modest uptick, ending the day at $65.37 which represents a slight increase of $0.22 or 0.34% from the prior close of $65.15. The stock opened at $64.86 and ...

Edward Lifesciences' Critical Care divestiture bodes well for its Structural Heart portfolio. Yet, macroeconomic issues raise worry for its operations.

Analysts have been eager to weigh in on the Healthcare sector with new ratings on TransMedics Group (TMDX – Research Report), Vertex ...

Fintel reports that on September 18, 2024, Jefferies downgraded their outlook for Edwards Lifesciences (NYSE:EW) from Buy to ...

Edwards Lifesciences (NYSE: EW), a medical technology company specializing in artificial heart valves, currently trades at $67 per share, about 50% lower than the peak level of $131 seen in December ...

Edwards Lifesciences Corporation (EW), headquartered in Irvine, California, provides products and technologies for structural ...